Leading Cardiovascular Researcher And PAD Treatment…
January 16, 2020
January 16, 2020
January 15, 2020
January 7, 2020
December 20, 2019
January 15, 2020
January 7, 2020
December 20, 2019
JanOne sees every day as an opportunity for fresh ideas to end the opioid epidemic, the worst drug crisis in our nation’s history.
As a NASDAQ-listed company, JanOne draws private-sector resources into this urgent fight. We seek innovative treatments—focusing on developing revolutionary, non-addictive drugs that kill pain, not people.
🚨JanOne is one step closer to finding a solution to non-addictive pain relief with the appointment of Dr. Christopher Kevil, Ph.D., to its scientific advisory board.
#JanOneSolution #KillPainNotPeople https://janone.com/leading-cardiovascular-researcher-and-pad-treatment-pioneer-dr-christopher-kevil-to-chair-janone-scientific-advisory-board/
💊Roughly 21 to 29% of patients prescribed #Opioids for chronic pain misuse them;
💊Between 8 and 12% develop an opioid use disorder;
➡️Learn more information on how #JanOne is working solutions to the opioid crisis: https://soo.nr/q6xn
Did you know?
• #Opioid painkillers such as oxycodone, hydrocodone & codeine have a stronger effect on women than on men?
• Women are more likely to develop an opioid addiction, and they also have a higher risk of relapse. #WomensHealth #JanOne
https://janone.com/opioid-addiction-men-vs-women/
